Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023
Innate Pharma will hold its Annual General Meeting (AGM) on May 12, 2023, at 10:30 a.m. CEST in Marseille, France. The meeting will be broadcast live, providing shareholders access to discuss the agenda and proposed resolutions.
Shareholders must register their shares at least two business days before the AGM. Those holding bearer shares need to secure a 'certificate of shareholding' from their brokers. Written questions must be submitted by email at least two business days prior to the meeting.
The company is actively developing immunotherapies for cancer patients through its innovative ANKET® platform and collaborations with partners like Sanofi and AstraZeneca.
- Live broadcast of AGM enhances shareholder engagement and transparency.
- Development of innovative cancer therapies through ANKET® technology.
- Strategic partnerships with biopharmaceutical companies, including Sanofi and AstraZeneca.
- None.
The Annual General Meeting will be broadcasted live by the Company
The Notice of Meeting of this AGM was published on
All documentation regarding this AGM will be published on the Company’s website along with the dial-in details for the live broadcast.
Precision regarding the AGM:
Only shareholders having registered their shares at least two business days prior to the date of the AGM, by zero hour
Shareholders holding “au porteur” (bearer) shares will need to obtain an “attestation de participation” (certificate of shareholding) from their brokers. This “attestation de participation” must be attached to the voting or proxy form.
Written questions from shareholders must be received the second business days prior to the AGM at the latest (by e-mail to investors@innate-pharma.fr).
Shareholders may obtain the legal documentation in preparation of the AGM (as described in article R. 225-83 of the French Code de Commerce) by sending a request by e-mail to investors@innate-pharma.fr.
About
Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types.
Headquartered in
Learn more about
Information about
ISIN code
|
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005537/en/
Investors
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Source:
FAQ
When is Innate Pharma's Annual General Meeting?
How can shareholders participate in the AGM?
What is the importance of the 'attestation de participation' for bearer shares?